Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ligand, Pharmaceutical Partners L.L.C. deal

LGND's Seragen Inc. subsidiary (Hopkinton, Mass.) sold to Pharmaceutical Partners its royalty rights to Zenapax daclizumab

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE